About XIEYI Media

Since 2013, based on the "Highland of China's Novel drug thought", TONACEA has started to build a new media matrix, and has carried out multi-level reports on frontier technology, policies and regulations, capital markets, industrial transformation, innovative figures and other bio-innovation related fields. At present, TONACEA continues to serve more than 500 customers.

 

On wechat, TONACEA accounts have accumulated more than 300,000 subscribers, mainly including leaders of government, parks, listed companies, innovative pharmaceutical enterprises, investment institutions, and front-line practitioners. In addition, TONACEA has entered community platforms such as Snowball, Zhihu and Weibo. TONACEA's brand exposure has exceeded 24 million.

图片名称
图片名称

TONACEA

Hot Event Analysis

Subdivision Track Count

Interview of Industry Figures

Think Tank View Output

图片名称
图片名称

XIEYI Release

Enterprise Dynamics

Personnel Change

Product Progress

Policy Release

图片名称
图片名称

TONACEA Biotech

Interpretation of Frontier Achievements

Introduction to Basic Scientific Research

图片名称
图片名称

TONACEA Micro Service

Industrial Activity Information

Theme Live Preview

Recommendation

mRNA tumor vaccine "seller", entering a golden age

When a Biotech company that has been acquired achieves rare growth

AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?

This road is long, but the threshold has already been crossed.

Novartis has failed, but Lp(a) has not yet

The Big Test for Lp(a)

Why is Biotech taking over Pfizer's ADC "abandoned child"?

Whose gamble?

With over $30 billion pouring in, what are major pharmaceutical companies seeking in the autoimmune track?

The "economic accounts" of immunology business development are being rewritten

After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant

determination for independence

Contact us

图片名称

Contribution and Writing articles

Yu Jing:15521120587

图片名称
图片名称

Media Release

Li Chun:19910611152

图片名称